UBS Sees Misunderstood Strength in Lifestance Health Group (LFST), Upgrades to Buy

UBS analyst Kevin Caliendo raised the rating of LifeStance Health Group, Inc. (NASDAQ:LFST) from Neutral to Buy on May 27, with an unchanged price target of $8.50.

Keep Reading →